Nuclear matrix associated protein PML: An arsenic trioxide apoptosis therapeutic target protein in HepG2 cells

Chinese Medical Journal

Volumn 116, Issue 1, 2003, Pages 93-98

  Yu, Ding ^a   Wang, Zihui ^a   Zhu, Liyuan ^a   Ec, Chew ^b  

^a PEKING UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Arsenic trioxide; HepG2 cell line; Nuclear matrix; PML protein

Indexed keywords

ARSENIC TRIOXIDE; DNA; DNA NUCLEOTIDYLEXOTRANSFERASE; MATRIX PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL NUCLEUS; CELL NUCLEUS MATRIX; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC KIT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; NICK END LABELING; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN TARGETING; WESTERN BLOTTING;

EID: 0037256555     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6:S3-S10.
2. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 1989;49:2525-2532.
3. Wang ZH, Yu D, Li HK, et al. Alteration of nuclear matrix protein composition of neuroblastoma cells after arsenic trioxide treatment. Anticancer Res 2001;21:493-498.
4. Yu D, Wang ZH, Cheng SB, et al. The effect of arsenic trioxide on the expression of Hsc and HNF4 in nuclear matrix proteins in HepG2 cells. Anticancer Res 2001;21:2553-2559.
5. Andre C, Guillemin MC, Zhu J, et al. The PML and PML/RAR alpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996;229:253-260.
6. Khan MM, Nomura T, Kim H, et al. Role of PML and PML-RAR alpha in Mad-mediated transcriptional repression. Mol Cell 2001;7:1233-1243.
7. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:3978-3983.
8. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
9. Shen ZY, Shen J, Cai WJ, et al. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000;5:155-158.
10. Jiang XH, Wong BC, Yuen ST, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;91:173-179.
11. Zhang TC, Cao EH, Li JF, et al. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35:1258-1263.
12. Ora I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000; 277: 179-185.
13. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6:S22-S28.
14. 3 induces apoptosis of the human B lymphoma cell line MBC-1. J Biol Regul Homeost Agents 2000;14:116-119.
15. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 2001;47:481-490.
16. 3 ) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;15;61:5432-5440.
17. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-4964.
18. Seol JG, Park WH, Kim ES, et al. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18:249-255.
19. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813.
20. Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci U S A 1988;85:121-125.
21. Rego EM, Wang ZG, Peruzzi D, et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 2001;193:521-529.
22. Shao W, Fanelli M, Ferrara FF, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-5178.
23. Wang ZH, Yam HF, Or PC, et al. Effects of all-trans-retinoic acid on human esophageal carcinoma cells and their nuclear matrices. Anticancer Res 1999;19:563-568.
24. Meyers S, Hiebert SW. Alterations in subnuclear trafficking of nuclear regulatory factors in acute leukemia. J Cell Biochem 2000;35:S93-S98.
25. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
26. Rousselot P, Labaume S, Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048.
27. Chan JY, Chin W, Liew CT, et al. Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer 1998;34:1015-1022.
28. Liu L, Qin S, Chen H, et al. An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes. Chin J Hepatol 2000;8:367-369.
29. Chen H, Qin S, Pan Q. Antitumor effect of arsenic trioxide on mice experimental liver cancer. Chin J Hepatol 2000;8:27-29.
30. Mologni L, Marchesi E, Nielsen PE, et al. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid. Cancer Res 2001;61:5468-5473.
31. Chen Z, Chen GQ, Shen ZX, et al. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 2001;38:26-36.
32. Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146-7153.